Beyond Air, Inc. Stock News

GARDEN CITY, N.Y., May 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on

Beyond Air (XAIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GARDEN CITY, N.Y., March 20, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused o

Beyond Air, Inc. (XAIR) Q3 2024 Earnings Call Transcript

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.43 per share a year ago.

Commercial demand for LungFit® PH increasing; manufacturing of upgraded devices is ramping up to meet growing demand

GARDEN CITY, N.Y., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on

No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts per million (PPM)

GARDEN CITY, N.Y., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on

Beyond Air, Inc. (NASDAQ:XAIR ) Q2 2024 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive

Provides fiscal year 2025 revenue guidance of $12 - $16 million US pilot trial of LungFit® PRO to treat viral community acquired pneumonia (VCAP) underway with data expected mid-calendar 2024 Beyond

First-in-human Phase 1 study demonstrates early clinical proof of concept Positive clinical biomarker data demonstrate evidence of immune system activation and the translation of the immunogenic respo

GARDEN CITY, N.Y., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on

GARDEN CITY, N.Y., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on

UNO therapy results in a more immunogenic tumor microenvironment (TME) as well as a systemic response that overcomes anti-PD-1 resistance